

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 7/31/2019
Gender: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 00/00/0000 00:00

B-Lymphoblastic Leukemia (B-ALL) Minimum Residual Disease Detection by Flow Cytometry

ARUP test code 3000724

Number of Markers 13 markers

B-All MRD Interpretation See Note

SAMPLE: Bone Marrow

IMPRESSION:
Small atypical immature B-cell population (See comment).

COMMENT:

There is a small atypical immature B-lineage population with low CD13/CD33 expression, concerning for recurrent/persistent B lymphoblastic leukemia/lymphoma; however, there are some phenotypic differences between this population and the previously identified atypical population from September 2023. Correlation with the original diagnostic phenotype as well as with other molecular markers of MRD, if available, may be helpful for overall interpretation of these findings. This atypical population accounts for 0.16% of viable leukocytes (The COG result is 0.109% of mononuclear cells, COG day 29 protocol used in evaluation).

In addition, an expanded population of myeloid blasts is also identified, accounting for approximately 10% of viable leukocytes. Clinical and morphologic correlation is needed.

Atypical B lineage population:

Positive: partial CD9, CD10, CD19, CD38, dim CD45, low CD13/CD33, partial low CD20, slightly low to intermediate CD58
Negative: most lack CD34
Aberrant expression: low CD13/CD33

The limit of detection for B-ALL blasts is 0.01% of mononuclear cells.

1. A previous B-ALL MRD bone marrow study from 9-19-2023 (Accession #23-263-401411) reported an abnormal immature B cell population accounting for 0.0086% of total nucleated cells.

ANALYSIS:

Nucleated cell differential:
35% Lymphocytes
5.5% Monocytes
9.3% Myeloid cells
40% Nucleated erythroid cells
10% CD34 positive myeloblasts

Viability: 100%

Markers run: CD3, CD9, CD10, CD19, CD20, CD13, CD33, CD34, CD38, CD45, CD58, CD71, Syto 16

This result has been reviewed and approved by [REDACTED]
[REDACTED] 11/27/2023

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 23-325-401167
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 1 of 2 | Printed: 12/4/2023 12:19:41 PM
4848

INTERPRETIVE INFORMATION: B-ALL MRD by Flow Cytometry

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
Number of Markers	23-325-401167	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00
B-All MRD Interpretation	23-325-401167	00/00/0000 00:00	00/00/0000 00:00	00/00/0000 00:00

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 23-325-401167
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 2 of 2 | Printed: 12/4/2023 12:19:41 PM
4848